Neurizon

Governance

Updates

Announcements

Home

Space Grotesk

Stockhead: Neurizon on the Health Kick Podcast

upload.jpg

In this episode, Tim Boreham from Stockhead catches up with Neurizon Therapeutics (ASX:NUZ) managing director and CEO Dr Michael Thurn for an update on the company’s ALS program and its lead candidate, NUZ-001.

Neurizon believes it has resolved the FDA’s concerns behind a clinical hold with new safety data, yet with the review process delayed the company remains hopeful of advancing to a pivotal Phase 2/3 trial on the Healy ALS Platform.

Dr Thurn explains what the hold means, how patient advocacy groups are stepping in, and why new data showing NUZ-001 may extend survival and slow disease progression has the company confident of a breakthrough.

To listen to the podcast, click the link below.

Stockhead: Health Kick Podcast: Fresh data keeps Neurizon on track in ALS fight